Osaic Holdings’s CRISPR Therapeutics CRSP Stock Holding History

Osaic Holdings’s Portfolio CRSP Stock Details CRSP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-3	Closed	-$885	–	7912
2025 Q3	$885	Hold	3	–	–	﹤0.01%	7399
2025 Q2	$885	Sell	3 -1	-25%	-$39	﹤0.01%	7195
2025 Q1	$20	Hold	4	–	–	﹤0.01%	7346
2024 Q4	$420	Buy	4 +3	+300%	+$142	﹤0.01%	7055
2024 Q3	$700	Hold	1	–	–	﹤0.01%	6943
2024 Q2	$1.48K	Hold	1	–	–	﹤0.01%	6705
2024 Q1	$2.83K	Hold	1	–	–	﹤0.01%	6331
2023 Q4	$2.5K	Hold	1	–	–	﹤0.01%	6456
2023 Q3	$1.24K	Hold	1	–	–	﹤0.01%	6770
2023 Q2	$2.4K	Hold	1	–	–	﹤0.01%	6599
2023 Q1	$1.45K	Buy	+1	New	+$49	﹤0.01%	6842

Other funds holding CRSP

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GSK plc London $599M AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Osaic Holdings's CRSP Position: Q1 2026 in Review

Osaic Holdings increased its CRISPR Therapeutics (CRSP) stake by 1.4% in Q1 2026, buying an estimated $44.6K and bringing the position to 60,056 shares worth $2.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1787.

Osaic Holdings first reported a position in CRSP in Q1 2020 and has held it in 25 quarters since. The position peaked at $6.2M in Q1 2024. 489 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

Osaic Holdings held 60,056 shares of CRISPR Therapeutics worth $2.86M as of Q1 2026.
Osaic Holdings bought 845 CRISPR Therapeutics shares in Q1 2026, an estimated $44.6K.
CRISPR Therapeutics made up ﹤0.01% of Osaic Holdings's portfolio in Q1 2026, its #1787 holding.
Osaic Holdings first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 25 quarters since.
Osaic Holdings's CRISPR Therapeutics position peaked at $6.2M in Q1 2024.
489 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Osaic Holdings's 13F filing for Q1 2026, filed 15 May 2026.